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Abstract
Background: Colorectal cancer is a common malignancy of the gastrointestinal tract. It is the
second cancer cause of death in females and third in males. Production of prolactin has been
reported with several tumours. However, elevated prolactin plasma levels in colorectal cancer
patients remained unclear.
Methods: In this cross sectional study serum prolactin and carcinoembryonic antigen (CEA)
concentrations were assayed using immunoradiometric assay kits, preoperatively in 47 patients,
and the results were compared with 51 age and sex matched controls.
Results: Prolactin and CEA concentration in patients were significantly more as compared with
controls. Hyperprolactinemia was found in 36 (76.6%) patients, while 28 (59.6%) had high level of
CEA.
Conclusions: Prolactin may be a better tumour marker than CEA in patients with colorectal
malignancy.
Background
Colorectal cancer is the third highest cause of cancer mor-
tality [1]. In Australia, the United Kingdom and the
United States, it is the second common cancer for women
after breast cancer (age-standardised incidence 22–33 per
100,000), and men after prostate or lung cancer (age-
standardised incidence 31–47 per 100,000). About
148,300 new cases are reported each year in the USA and
56,600 Americans die annually from this cause [2]. Prog-
nostic factors are very important for the evaluation, judg-
ment and optimal treatment of patients with cancer.
Carcinoembryonic antigen (CEA) has been recognized as
a serum marker for colorectal cancer in the past three dec-
ades [3] and has an important role in the management of
colorectal cancer [4].
Prolactin (PRL) is a hormone with multiple biological
actions, synthesized by the anterior pituitary gland [5]
and is best known for its roles in the mammary gland.
However, it is now revealed that PRL is able to exert its
effects on additional cells and tissues (decidual cells of the
placenta, bone, brain, lymphocytes and breast epithelial
cells) [6,7]. PRL is secreted not only by lactotrophic cells
of the pituitary gland but also by a variety of other normal
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tissues and human tumours [8] including malignant
tumours of the lung[9], kidney[10], uterine[11], ovary
[12], and breast[13]. Increase of PRL in colorectal cancer
is unclear. Bhatavdekar, et al reported a significantly
higher preoperative prolactin levels in patients with color-
ectal carcinoma [14], While, Indinnimeo et al and Carlson
et al could not confirm hyperprolactinemia in patients
with colorectal cancer. [15,16] These conflicting results do
not support the hypothesis of increasing level of PRL in
colorectal carcinoma.
The aim of this study was to see whether PRL levels are
increased in colorectal cancer and to compare the preop-
erative serum levels of PRL and CEA concentrations in
colorectal cancer patients; also we intended to find the
possible correlation between hyperprolactinemia and the
stage of colorectal cancer.
Methods
This cross-sectional study included 47 patients with color-
ectal cancer (18 women, 29 men; mean age 55.4 years,
range 32–81) and 51 non-cancer patients (21 women, 30
men; mean age 58.5 years, range 20–81), who were candi-
dates of colectomy. All patients were admitted in Shariati
general hospital affiliated to Tehran University of Medical
Sciences (TUMS) from April 2001 to January 2003. All
women in the study were postmenopausal. None of the
patients were on any drugs known to increase plasma pro-
lactin levels in the last 6 months prior to the study and
were not affected by endocrine, renal, and psychiatric dis-
orders. There was no history of rectal bleeding and family
history of colorectal cancer. Peripheral venous blood sam-
ples were daily collected from seven days before the oper-
ation to measure serum PRL and CEA levels. Blood
samples were collected between 07:30 a.m. and 09:30
a.m. to avoid diurnal variation of PRL. Serum prolactin
levels were measured with immunoradiometric assay
(IRMA) kits produced by Kavoshian co (Tehran-Iran).
Serum CEA levels were assayed by IRMA, who used kits
from IMMUNOTECH co (Marseille-France). The PRL and
CEA assays were carried out within 10 days of sampling.
The cut off levels for PRL and CEA were 20 ng/ml and 5
ng/ml serum respectively [17,18]. Stages of cancer were
determined by pathology assessment of neoplastic
specimens.
The study was approved by the Vice-Chancellor of Resear-
chEthic Committee of TUMS.
The data evaluated by Chi-square test and T test using the
Statistical Package of Social Science (SPSS Inc., Chicago,
IL) for Windows version 11.5. A P-value of <0.05 was con-
sidered statistically significant.
Results
The number of male and female participants was 29 and
18 in case and 30 and 21 in control group.
We compared serum PRL and CEA level of 47 patients
with 51 healthy controls. There was no significant differ-
ence between the age and the sex distribution of the
patients and control groups.
Mean PRL serum level in colorectal cancer group was 21.6
± 8.1versus 10.5 ± 4.6 in control group, which was signif-
icantly different (p < 0.0001). In other words 36 patients
showed hyperprolctinemia (76.7%) while there was only
one such patient in the control group (1.9%).
CEA level in 59.6% of the cancer group was above the nor-
mal compared with 1.9% of controls (P < 0.0001).
Out of 47 patients in the cancer group 9 were in stage I
(19.1%), 19 in stage II (40.4%), 10 in stage III (21.3 %)
and 9 in stage IV (19.1%). Hyperprolactinemia and high
CEA concentrations were found in all stages (figure 1).
Discussion
Prognostic factors are crucial for the evaluation and opti-
mal treatment of patients with cancer [17]. Therefore
tumour markers have a greater role in the assessment of
therapeutic response. Measurements of serum tumour
markers may be helpful in detecting the metastatic process
while still in the sub clinical phase [15]. The ectopic secre-
tion of hormones like PRL by non-endocrine neoplasms
is well recognized and used as therapeutic monitoring
[15].
The main source of PRL is the pituitary gland, but in recent
years, some studies have reported hyperprolactinemia in
patients with breast [13], lung [9], prostate and ovary
tumours [12].
Elevated circulatory levels of this hormone have also been
detected in colorectal cancer. Bhatavdekar et al reported a
high preoperative serum concentration of PRL in patients
with colorectal cancer [14]. Ilan et al. reported elevated
levels of PRL in 53% of the patients with colorectal malig-
nancy [19]. Baert et al, in contrast didn't determine preop-
erative hyperprolactinemia in a series of 32 patients and
their study didn't support the hypothesis of ectopic prol-
actin production by colorectal cancer [20]. Indinnimeo, et
al found no hyperprolactinemia and prolactin positive
immunostaining in colorectal cancer [15]. Previous stud-
ies, that reported normal levels of PRL [20,15], have sug-
gested such factors as renal, endocrine and psychiatric
disorders, medications and premenopausal situation may
be the cause of hyperprolactinemia in patients with color-
ectal neoplasms. In the present study, patients with aboveBMC Cancer 2004, 4:97 http://www.biomedcentral.com/1471-2407/4/97
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factors were excluded and our results confirmed preoper-
ative hyperprolactinemia in colorectal cancer. We found
no correlation between the plasma PRL concentration and
the stage of the tumour.
CEA present in blood during fetal life, falls to very low lev-
els in most adults, and circulates in high concentrations in
patients with some cancers [21]. CEA is over expressed in
most colorectal cancers and is an important tumour
marker in the management of colorectal cancer. A preop-
erative high CEA value suggests advanced disease either
locally or with a distant metastasis. The preoperative
serum CEA level can be a useful predicting factor regard-
ing the outcome of the surgical operation [4]. In the
present study we found that serum PRL and CEA levels are
increased in patients with colorectal cancer but the greater
portion of the patients had an increased level of PRL com-
pared with elevated level of CEA. Considering the fact that
laboratory cost for detecting CEA is higher than PRL, We
suggest PRL as a valuable tumour marker in colorectal
cancer. There are studies that support the tumour marker
value of PRL [18,22] and studies that do not [16,20].
Conclusions
This study demonstrates that PRL, a pituitary gland hor-
mone, is elevated in colorectal cancer. Moreover, our
results show that PRL may be a better tumour marker than
CEA in patients with colorectal malignancy. However, fur-
ther prospective studies are warranted to better under-
stand the evaluation of PRL as a prognostic factor, and to
follow up patients after operation to determine the possi-
ble correlation between PRL levels, survival and response
to therapy.
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